The unlimited supply and genetic modifiability of human pluripotent stem cells (hPSCs) make them promising candidates for therapeutic applications. However, scaling protocols to generate large yields of functional hPSC-derived cells for treatment remains a challenge in the field. Standardized protocols such as those developed by STEMCELL Technologies may help researchers to overcome these challenges.

To learn more, join Dr. Leon Lin as he presents a robust and standardized protocol using the STEMdiff™ Hematopoietic Kit to generate over 1 million hPSC-derived hematopoietic progenitor cells (HPCs) per mL in 10 -12 days via monolayer or 3D suspension cultures. These HPCs can be further differentiated into functional myeloid cells to support preclinical development in cell and gene therapy.